| 2025-11-10 |
详情>>
股本变动：
变动后总股本1177.65万股
|
| 2025-11-10 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-10.42美元,归母净利润-7711.1万美元,同比去年增长28.55%
|
| 2025-08-21 |
详情>>
内部人交易：
Taylor Carolyn E.股份增加418.00股
|
| 2025-08-18 |
复牌提示：
2025-08-18 09:33:07 停牌，复牌日期 2025-08-18 09:38:07
|
| 2025-08-11 |
详情>>
业绩披露：
2025年中报每股收益-6.8美元,归母净利润-4510.1万美元,同比去年增长51.87%
|
| 2025-08-11 |
财报披露：
美东时间 2025-08-11 盘后发布财报
|
| 2025-05-12 |
详情>>
业绩披露：
2025年一季报每股收益-2.84美元,归母净利润-1682.9万美元,同比去年增长-12.65%
|
| 2025-03-31 |
股东大会：
将于2025-05-08召开股东大会
会议内容 ▼▲
- 1.The election of the eight director nominees named in the Proxy Statement to hold office until the next annual meeting of shareholders;
2.The ratification of the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025;
3.To authorize the Company’s Board of Directors (the “Board”), in its discretion at any time within one year after shareholder approval is obtained, to effect one or more reverse stock splits of the then-outstanding shares of the Company’s common stock, having an aggregate ratio of not less than one-for-two (1:2) and not greater than one-for-two-hundred-fifty (1:250), with the exact ratio, number and timing of the reverse stock splits to be determined by the Company’s Board and included in a public announcement (the “Reverse Stock Split Proposal”);
4.To approve an amendment to the Company’s 2020 Stock Incentive Plan (the “Incentive Plan”) to increase the number of shares of Common Stock available for awards under the Incentive Plan by 1,000,000 shares (the “Amendment to the Incentive Plan Proposal”);
5.To approve Tonix Pharmaceuticals Holding Corp. 2025 Employee Stock Purchase Plan;
6.To approve, on an advisory basis, the compensation of the Company’s named executive officers;
7.To approve, on an advisory basis, the frequency with which the Company should conduct future shareholder advisory votes on named executive officer compensation;
8.The consideration of any other matters that may properly come before the Annual Meeting.
|
| 2025-03-18 |
详情>>
业绩披露：
2024年年报每股收益-176.6美元,归母净利润-1.3亿美元,同比去年增长-11.47%
|
| 2025-02-05 |
详情>>
拆分方案：
每100.0000合并分成1.0000股
|
| 2024-11-12 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-4.66美元,归母净利润-1.08亿美元,同比去年增长-20.81%
|
| 2024-09-23 |
股东大会：
将于2024-10-30召开股东大会
会议内容 ▼▲
- 1.The approval of a proposal to authorize the Company’s Board of Directors (the “Board”), in its discretion at any time within one year after shareholder approval is obtained, to effect a reverse stock split of then-outstanding shares of the Company’s common stock, at a ratio of not less than one-for-two (1:2) and not greater than one-for-hundred (1:100), with the exact ratio to be determined by the Company’s Board and included in a public announcement (the “Reverse Stock Split Proposal”);
2.The approval of an amendment to the Company’s Articles of Incorporation, as amended, to increase the Company’s authorized shares of common stock to 1,000,000,000 in the event a reverse stock split of our common stock is effectuated prior to approval of the Reverse Stock Split Proposal (the “Proposal to Increase Authorized Shares”);
3.The consideration of any other matters that may properly come before the Special Meeting.
|
| 2024-08-16 |
详情>>
业绩披露：
2024年中报每股收益-27.33美元,归母净利润-9371.5万美元,同比去年增长-52.73%
|
| 2024-06-10 |
详情>>
拆分方案：
每32.0000合并分成1.0000股
|
| 2024-05-13 |
详情>>
业绩披露：
2024年一季报每股收益-0.18美元,归母净利润-1493.9万美元,同比去年增长54.74%
|
| 2024-04-15 |
股东大会：
将于2024-05-22召开股东大会
会议内容 ▼▲
- 1.The election of the eight director nominees named in the Proxy Statement to hold office until the next annual meeting of shareholders;
2.The ratification of the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024;
3.The approval a proposal to authorize the Company’s Board of Directors (the “Board”), in its discretion at any time within one year after stockholder approval is obtained, to effect a reverse stock split of then-outstanding shares of the Company’s common stock, at a ratio of not less than one-for-two (1:2) and not greater than one-for-fifty (1:50), with the exact ratio to be determined by the Company’s Board and included in a public announcement (the “Reverse Stock Split Proposal”);
4.To approve, for the purpose of complying with the applicable provisions of The Nasdaq Stock Market LLC (“Nasdaq”) Listing Rule 5635(d), the repricing of up to 6,950,000 Common Warrants issued August 2023, 8,900,000 Series A Warrants issued October 2023, 8,900,000 Series B Warrants issued October 2023, 34,824,328 Series C Warrants issued December 2023, and 34,824,328 Series D Warrants issued December 2023 (the “Warrant Repricing Proposal”);
5.The consideration of any other matters that may properly come before the Annual Meeting.
|
| 2024-04-01 |
详情>>
业绩披露：
2023年年报每股收益-6.85美元,归母净利润-1.17亿美元,同比去年增长0.19%
|
| 2024-01-08 |
股东大会：
将于2024-02-15召开股东大会
会议内容 ▼▲
- 1.To approve, for the purpose of complying with the applicable provisions of The Nasdaq Stock Market LLC (“Nasdaq”) Listing Rule 5635(d), the issuance of up to 162,162,162 shares of our common stock issuable upon the exercise of our outstanding Series C warrants and Series D warrants issued to institutional investors in connection with our offering that closed on December 22, 2023 (the “Warrant Issuance Proposal”);
2.To approve the adjournment of the Special Meeting, if necessary, if a quorum is present, to solicit additional proxies if there are not sufficient votes to approve the Warrant Issuance Proposal.
|
| 2023-12-26 |
股东大会：
将于2024-01-25召开股东大会
会议内容 ▼▲
- 1.To approve an amendment to the Company’s Articles of Incorporation, as amended, to increase the Company’s authorized shares of common stock from 160,000,000 to 1,000,000,000;
2.To approve the adjournment of the Special Meeting, if necessary, if a quorum is present, to solicit additional proxies if there are not sufficient votes to approve the amendment to the Company’s Articles of Incorporation.
|
| 2023-11-09 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-7.4美元,归母净利润-8933.6万美元,同比去年增长-7.9%
|
| 2023-08-10 |
详情>>
业绩披露：
2023年中报每股收益-5.88美元,归母净利润-6136.1万美元,同比去年增长-14.03%
|
| 2023-05-10 |
详情>>
拆分方案：
每25.0000合并分成4.0000股
|
| 2023-03-17 |
股东大会：
将于2023-05-05召开股东大会
会议内容 ▼▲
- 1.The election of the eight director nominees named in the Proxy Statement to hold office until the next annual meeting of shareholders;
2.The ratification of the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023;
3.The approval of the Tonix Pharmaceuticals Holding Corp. 2023 Employee Stock Purchase Plan;
4.The consideration of any other matters that may properly come before the Annual Meeting.
|
| 2022-11-07 |
股东大会：
将于2022-12-13召开股东大会
会议内容 ▼▲
- 1.To approve an amendment to the Company’s Articles of Incorporation, as amended, to increase the Company’s authorized shares of Common Stock from 150,000,000 to 1,000,000,000;
2.To approve the adjournment of the Special Meeting, if necessary, if a quorum is present, to solicit additional proxies if there are not sufficient votes to approve the amendment to the Company’s Articles of Incorporation.
|
| 2022-07-05 |
股东大会：
将于2022-08-05召开股东大会
会议内容 ▼▲
- 1.To approve an amendment to the Company’s Articles of Incorporation, as amended, to increase the Company’s authorized shares of Common Stock from 50,000,000 to 150,000,000;
2.To approve the adjournment of the Special Meeting, if necessary, if a quorum is present, to solicit additional proxies if there are not sufficient votes to approve the amendment to the Company’s Articles of Incorporation.
|
| 2022-05-17 |
详情>>
拆分方案：
每32.0000合并分成1.0000股
|
| 2022-03-18 |
股东大会：
将于2022-05-06召开股东大会
会议内容 ▼▲
- 1.The election of the seven director nominees named in the Proxy Statement to hold office until the next annual meeting of shareholders;
2.The ratification of the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022;
3.The approval of the Tonix Pharmaceuticals Holding Corp. 2022 Employee Stock Purchase Plan;
4.The approval, on an advisory basis, of the compensation of the Company’s named executive officers;
5.The consideration of any other matters that may properly come before the Annual Meeting.
|
| 2021-12-23 |
股东大会：
将于2022-02-10召开股东大会
会议内容 ▼▲
- 1.To approve an amendment to the Company’s Articles of Incorporation, as amended, to increase the Company’s authorized shares of common stock from 800,000,000 to 1,600,000,000;
2.To approve the adjournment of the Special Meeting, if necessary, if a quorum is present, to solicit additional proxies if there are not sufficient votes to approve the amendment to the Company’s Articles of Incorporation.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-03-31 |
股东大会：
将于2021-05-07召开股东大会
会议内容 ▼▲
- 1.To elect the seven director nominees named in the Proxy Statement to hold office until the next annual meeting of shareholders;
2.To ratify the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021;
3.To consider any other matters that may properly come before the Annual Meeting.
|
| 2021-02-11 |
股东大会：
将于2021-03-26召开股东大会
会议内容 ▼▲
- 1.To approve an amendment to the Company’s Articles of Incorporation, as amended, to increase the Company’s authorized shares of common stock from 400,000,000 to 800,000,000;
2.To approve the adjournment of the Special Meeting, if necessary, if a quorum is present, to solicit additional proxies if there are not sufficient votes to approve the amendment to the Company’s Articles of Incorporation.
|
| 2020-07-21 |
股东大会：
将于2020-06-26召开股东大会
会议内容 ▼▲
- 1.To approve an amendment to the Company’s Articles of Incorporation, as amended, to increase the Company’s authorized shares of common stock from 150,000,000 to 400,000,000;
2.To act on such other matters as may properly come before the meeting or any adjournment there.
|
| 2020-07-21 |
股东大会：
将于2020-08-28召开股东大会
会议内容 ▼▲
- 1.To approve an amendment to the Company’s Articles of Incorporation, as amended, to increase the Company’s authorized shares of common stock from 150,000,000 to 400,000,000;
2.To act on such other matters as may properly come before the meeting or any adjournment there.
|
| 2020-03-30 |
股东大会：
将于2020-05-01召开股东大会
会议内容 ▼▲
- 1.To elect the seven director nominees named in the Proxy Statement to hold office until the next annual meeting of shareholders;
2.To ratify the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2020;
3.To approve the Tonix Pharmaceuticals Holding Corp. Amended and Restated 2020 Stock Incentive Plan;
4.To approve the Tonix Pharmaceuticals Holding Corp. 2020 Employee Stock Purchase Plan;
5.To act on such other matters as may properly come before the meeting or any adjournment there.
|
| 2019-12-13 |
股东大会：
将于2020-01-16召开股东大会
会议内容 ▼▲
- 1.To approve an amendment to the Company’s Articles of Incorporation, as amended, to increase the Company’s authorized shares of common stock from 15,000,000 to 150,000,000;
2.To approve the Tonix Pharmaceuticals Holding Corp. 2020 Stock Incentive Plan;
3.To approve, for purposes of complying with applicable NASDAQ Listing Rules, the potential issuance and sale of 20% or more of the Company’s common stock pursuant to the Company’s purchase agreement with Lincoln Park Capital Fund LLC pursuant to which Lincoln Park Capital Fund LLC has agreed to purchase from us, from time to time, up to $15,000,000 of our common stock;
4.To act on such other matters as may properly come before the meeting or any adjournment thereof.
|
| 2019-11-01 |
详情>>
拆分方案：
每10.0000合并分成1.0000股
|
| 2019-03-18 |
股东大会：
将于2019-05-03召开股东大会
会议内容 ▼▲
- 1.To elect the eight director nominees named in the Proxy Statement to hold office until the next annual meeting of shareholders;
2.To ratify the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2019;
3.To approve the Tonix Pharmaceuticals Holding Corp. 2019 Stock Incentive Plan;
4.To approve the Tonix Pharmaceuticals Holding Corp. 2019 Employee Stock Purchase Plan;
5.To approve an amendment to the Company’s Articles of Incorporation, as amended, to increase the Company’s authorized shares of common stock from 15,000,000 to 150,000,000;
6.To approve, on an advisory basis, the compensation of the Company’s named executive officers;
7.To approve, on an advisory basis, a three-year frequency with which the Company should conduct future shareholder advisory votes on named executive officer compensation;
8.To act on such other matters as may properly come before the meeting or any adjournment there.
|
| 2018-11-28 |
详情>>
拆分方案：
每10.0000合并分成1.0000股
|
| 2018-04-19 |
股东大会：
将于2018-06-08召开股东大会
会议内容 ▼▲
- 1.To elect the nine director nominees named in the Proxy Statement to hold office until the next annual meeting of shareholders;
2.To ratify the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2018;
3.To approve the Tonix Pharmaceuticals Holding Corp. 2018 Stock Incentive Plan;
4.To approve the Tonix Pharmaceuticals Holding Corp. 2018 Employee Stock Purchase Plan;
5.To act on such other matters as may properly come before the meeting or any adjournment there.
|
| 2017-05-02 |
股东大会：
将于2017-06-16召开股东大会
会议内容 ▼▲
- 1.To elect the eight director nominees named in the Proxy Statement to hold office until the next annual meeting of shareholders;
2.To ratify the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2017;
3.To approve the Tonix Pharmaceuticals Holding Corp. 2017 Stock Incentive Plan;
4.To approve an amendment to the Company’s Articles of Incorporation, as amended, to increase the Company’s authorized shares of common stock from 15,000,000 to 150,000,000;
5.To approve an amendment to the Company’s Articles of Incorporation, as amended, to increase the maximum size of the board of directors;
6.To approve an amendment to the Company’s Articles of Incorporation, as amended, to clarify that, to the fullest extent permitted by Nevada law, our directors or officers shall not be personally liable to us or our shareholders for damages for breach of such director’s or officer’s fiduciary duty;
7.To approve an amendment to the Company’s Articles of Incorporation, as amended, to clarify that advancement of expenses is required in connection with any indemnification claim;
8.To act on such other matters as may properly come before the meeting or any adjournment there.
|
| 2017-03-15 |
详情>>
拆分方案：
每10.0000合并分成1.0000股
|
| 2016-03-25 |
股东大会：
将于2016-05-11召开股东大会
会议内容 ▼▲
- 1.To elect the eight director nominees named in the Proxy Statement to hold office until the next annual meeting of shareholders;
2.To ratify the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2016;
3.To approve the Tonix Pharmaceuticals Holding Corp. 2016 Stock Incentive Plan;
4.To approve, on an advisory basis, the compensation of the Company’s named executive officers;
5.To act on such other matters as may properly come before the meeting or any adjournment there.
|
| 2015-04-22 |
股东大会：
将于2015-06-08召开股东大会
会议内容 ▼▲
- 1.To elect the eight director nominees named in the Proxy Statement to hold office until the next annual meeting of shareholders;
2.To ratify the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2015;
3.To act on such other matters as may properly come before the meeting or any adjournment there.
|